{"name":"Clinuvel Pharmaceuticals Limited","slug":"clinuvel-pharmaceuticals-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxObFgwYmhSMDgtQURadHV0c09yVU9GY004ajctYzdJcDd0MVBjV0ZSOXU5WktaMzBRNlNDRW5wbDE2V3NDaDlvallWTG9QTDdveE1BLWc0eG5BNllLZ2o4OGZleTI1WGxkQWJvUGFtTmpUTGEtaHViclJ5dWVlUy1DV1BiRlNJc0tZeVlhSlJyN3M0elNNT0VRbHNqOVIxTWRyWGVHRg?oc=5","date":"2026-01-27","type":"trial","source":"BioWorld News","summary":"Tanabe’s dersimelagon hits phase III endpoint in rare disorder - BioWorld News","headline":"Tanabe’s dersimelagon hits phase III endpoint in rare disorder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQWmRHN3VmUGdSYzdTcU0xeGJUWGl0T2lxUlRnN0ZkbVRIZGR4amZDWWtiOVJaNzc3ZHAxTUNOYWJFZUwxQnZNYWVMcWl4d0ZqSHdLQzRTbHBsanZkMHlEZ09tSHBrUHh1Qi11XzlvRExydkNJbXNsQUdoRldGY3M2d0dtZmdDbzlZQ2tIUkNTRHpKX3Qzazk4SGtqclNTbC1MVXRRempDbm4zejha?oc=5","date":"2026-01-16","type":"trial","source":"The Pharma Letter","summary":"Oral dersimelagon clears Phase III bar in ultra-rare EPP and XLP - The Pharma Letter","headline":"Oral dersimelagon clears Phase III bar in ultra-rare EPP and XLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPdVdHdklDZW0xQ3M0d092OWR2eGp6aXF0eGQ2aURpeTZfODF4YWIxakpHNTZ4ck15emRJbVFyOVptTnUwdU9oTVVNa3NCY0VsM2tIOGZaeWF1TjF0d2RZX01tNjM2V25rWHpCTFlUU0MtazI3OF9wVmZuYThGRUlmbVZhRXQyU3ItdGRyS3VGYnA5eHZuX0tRWVlJNnJ2b2FyX3RYZ3ZYR0JQY01JN3FPTXlJWFpWeUlKSXE4TlRuNlI?oc=5","date":"2025-12-08","type":"pipeline","source":"BioSpace","summary":"CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies - BioSpace","headline":"CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-03","type":"pipeline","source":"Business Wire","summary":"United States Vitiligo Forecast Report 2025: A $320+ Million Market by 2033 Featuring Incyte, BMS, Clinuvel Pharmaceuticals, Astellas Pharma, Baxter, Pfizer, Dr. Reddy's Laboratories - ResearchAndMark","headline":"United States Vitiligo Forecast Report 2025: A $320+ Million Market by 2033 Featuring Incyte, BMS, Clinuvel Pharmaceutic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQVkh1akpJd2ZvbE1TUUxkd3dELVE0bWM1V1RuTU42akFCQ3JRY2pfZmZNTE90bS1zaXZuRDZTVjZXMUJyRUxvVGxpdWFUMFdOVWJEVkJodFBhNndWVWk0OTVucU9oRWJFSFRZWndDeWMtYlVLREE0ZzhHZGlaQUkweWFFdWZ0RFlsLVEtUkRmVFhtSlNWQmZzNkktMVRXNG9jVmxnNEg2TmtKSkdDR2twUTAzQlJNUQ?oc=5","date":"2025-09-29","type":"pipeline","source":"Stockhead","summary":"Health Check: Biotech investors reckon Trump’s tariffs may not be such a bitter pill - Stockhead","headline":"Health Check: Biotech investors reckon Trump’s tariffs may not be such a bitter pill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNbHdDaUxBUGkxWXF3amJfaW12U3J1WFYwakExWmhhU0YzU05LWFBUWnhLSVdUaGlFc0liRlBaMUdpZ25oNTl4NDN4QnpMNHk1WnEzNTBpZFlLbEwyNHNWTHRzLXlXR2VMTlB1YTdaY183aVVwSF92NVpZdUxsT0NFZkNRUWMwRF84VnI3M2VpZldtcUtCQ09OSXd4ejQ?oc=5","date":"2025-09-28","type":"pipeline","source":"Yahoo Finance","summary":"CLINUVEL to advance novel pharmaceutical formulations in preclinical program - Yahoo Finance","headline":"CLINUVEL to advance novel pharmaceutical formulations in preclinical program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQMkFqR3R5Mmw4WWdUTWVvN0xYM3R4YjVta1RrN0hZSnlNci02aHUtM2FVWEY3TXB2bDk2bEU5Sy1FOVZBZ0JScmtLdjZMc2lfMU9WNVIxblVBSkt2ZGFrNjVsdVNoU0RoS1o0MU9wNnh3RU84ZFJYWVFld1NmY3l2UmtRNnhJdFVpbnNneGhlQWwyNnpKa1Fyak1wVmNiTVgzUjNPdFhLZ0xIZF9FclItdmt0cG02UlVGM1pSdWEtZ2NZTUZWMEYySlJSbk82R090X0ZaZWw0dzluYVhkS3kzTXJTZTBySmJHNXFIcWF4QUNrQXY0UW9ROVhwaVVjTDFUUEhFMHAtaldMemhHTC1kOUVKRmZnRWFKaXZoRm1hOA?oc=5","date":"2025-08-14","type":"trial","source":"GlobeNewswire","summary":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma - GlobeNewswire","headline":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQVkNnV3NueVV5a1o0WVhsSUZDVHFlTTdlTnRNWS00NHg2Zk5TVDdyRjZ4c2ZjRnNQT3pncTB1RjBLaFh4WFRyMGcwOGhuWDVEX3dsLUMzTU9hSUNwWno1VklqWk5Cai1iSE5lS0pkVGs3eEN3c3lyZVZ0Z3o0cmtWazNQMzVPa0s4UDVRelNQX0d5ZThvMHh0Vnk3UHN1MVU3WThBbHdnU3hoM0pYTGN4OGdHZ3hBY3ltczBnanBFSURTOGNSR0l1OGVDcFBlWWwwdWNySHMzSFlTcUlZSDJCOE9mU1NFOHFsZFRGRy1OX0tDZ9IB9wFBVV95cUxPRlZvVXZ1a3F4S3NPUlgweTNXWmNaa0ZjSHV4clFRMllfOUtQbkJ3MGlXMG50eHVWa1B4cXcwWEs2OGs5ck95a0NiNW1JQUtUSVZyc1J3WUZUNnZOUU0taUQ1ODZQRDBrdUdvcWRMWmNYZ0RnWmlWMnpIY1ZBd3VSS0JCZ2dycDBtZXRTeUVvTTV5UFg3MU9NSUlFUm9oN3FISnJEX0k3ay0xNlZwaWpKaUZPck9vZnkxbFJIVHRRWFM5OVdUNk9lSzdtbzQ2MHpVWjJ6RGdySWdxVm1ZcGVQUnNXNEttazhJbERrYi1nTExBNk4ycnpn?oc=5","date":"2025-07-21","type":"pipeline","source":"simplywall.st","summary":"It's A Story Of Risk Vs Reward With Clinuvel Pharmaceuticals Limited (ASX:CUV) - simplywall.st","headline":"It's A Story Of Risk Vs Reward With Clinuvel Pharmaceuticals Limited (ASX:CUV)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxPNENwZFNOUy00TGpWSmJHbWV1V2UwQU5QWjAyd2owSUdlcWV2aThqZDktLXdJLVJubmVIMFQtal8zRlgxTEY2T1U0eWFYU2d3enMwMXdYaHN4NjZKSGxOTTRTdzRXX2tFVzZOSlFLYW5ZOTE2Y1FIcXB5dFhFd2ZfdS1jdDRXVUpvTG1mUjZrYk9tcFIzbGl3YWVWZV90T3EwZ1pSeEVRdWhVT0dOb1JMZnMzMGJ1VVhWeUVxdG1hRGVia04zNnZGVTRKQUUxU3FRN0dFRGtHejlKRnJmMEx4R2x5Xzc1QVAyNS16R1A3WkFxR1VvZHdyUTREWnJYa2h2cUJlUVVmN29XMFVxZWk0MEtUdTlSWGs3Y0VNdnNCMXNCOUlieDZyTHgtX2FpYnJBN1E?oc=5","date":"2025-07-14","type":"pipeline","source":"PR Newswire","summary":"MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight - PR Newswire","headline":"MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQejV1Y1hpdzBRQUJ0dTdpOXlBam9jUi1fT0JlWWZZLUZURHJqcjM1dmNneUJqY2lHVTBvZUc4Q241SE1BemZSeTlfNTZjNU56TUpKdVB0bFF2X0ZoOU0wdTBmVDVPeGx4LVBES2tRZ0hvNjNQV3BMMFViWTRyXzVSVzktMG51OGE2c0RuODNEQ3RYT2JpZWFqYWNiN2diMjRMM2JzQg?oc=5","date":"2025-07-03","type":"pipeline","source":"The Motley Fool Australia","summary":"These healthcare stocks could be set to double according to broker - The Motley Fool Australia","headline":"These healthcare stocks could be set to double according to broker","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5XTkMzU0VRMGZjVEpQdTdhRldyc2ZXUDZrek1BVExualV3c3FVMmxGYkpEMmVOVkR5cnJmaUZFb0wyMUpveDk4V3ZBX2ZiNUxBLXI5bEt0YnFXRnNXaGNuWjlfUXdaV3oyRHRGSWs2ZjRWamRReE9JUnN3NXY0UQ?oc=5","date":"2023-07-26","type":"pipeline","source":"pharmaphorum","summary":"NICE won't budge on rejection of rare disease drug - pharmaphorum","headline":"NICE won't budge on rejection of rare disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOSWQyMk14aVVtTExneDZDaG0taEFiT2pMdHByUmFKTjdUX3FtS2dOelo2UkhKUFhEUVdBX1ZQN2JTTm8xR3lyYnMzXzNKbWpQZXJaX1F1SU9haldSVlVpNHZWUlRqSFNoUXZrZ0ZSNkRFakxkeGxtMnRlZ3NSZ1Utd2xaMzRVOTd3NFRzb1gyZzdxOTVvbmExd0NTcnk?oc=5","date":"2019-10-09","type":"regulatory","source":"BioPharma Dive","summary":"Australian drugmaker’s decade-long journey ends in FDA approval - BioPharma Dive","headline":"Australian drugmaker’s decade-long journey ends in FDA approval","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}